Photo from wikipedia
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of effective screening tests. CA199, the standard biomarker for PDAC management, is not sufficiently reliable for early… Click to show full abstract
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of effective screening tests. CA199, the standard biomarker for PDAC management, is not sufficiently reliable for early diagnosis. This prospective study aimed to evaluate whether circulating tumor cells (CTCs) could complement or perform better than CA199 in determining PDAC.
Keywords:
circulating tumor;
diagnosis pancreatic;
diagnosis;
tumor cells;
combination circulating
Journal Title: Journal of Clinical Laboratory Analysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Laboratory Analysis
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!